EC Number   |
Disease |
PubMed ID |
Title of Publication  |
Category |
Confidence Level |
|---|
    2.5.1.21 | Neoplasms |
21568272 |
(--)-Xanthatin selectively induces GADD45? and stimulates caspase-independent cell death in human breast cancer MDA-MB-231 cells. |
ongoing research
therapeutic application
unassigned |
4
1
0 |
| 2.5.1.21 | Malaria |
18198825 |
2-Oxotetrahydroquinoline-based antimalarials with high potency and metabolic stability. |
therapeutic application
unassigned |
3
0 |
| 2.5.1.21 | Neoplasms |
32877662 |
20(S)-Rg3 upregulates FDFT1 via reducing miR-4425 to inhibit ovarian cancer progression. |
ongoing research
therapeutic application
unassigned |
1
2
0 |
| 2.5.1.21 | Ovarian Neoplasms |
32877662 |
20(S)-Rg3 upregulates FDFT1 via reducing miR-4425 to inhibit ovarian cancer progression. |
ongoing research
therapeutic application
unassigned |
1
2
0 |
| 2.5.1.21 | Neuroblastoma |
20053345 |
24S-hydroxycholesterol effects on lipid metabolism genes are modeled in traumatic brain injury. |
ongoing research
unassigned |
1
0 |
| 2.5.1.21 | Neoplasms |
19515462 |
3D-QSAR with the aid of pharmacophore search and docking-based alignments for farnesyltransferase inhibitors. |
causal interaction
therapeutic application
unassigned |
4
4
0 |
| 2.5.1.21 | Neoplasms |
26706114 |
8-Hydroxyquinoline-based inhibitors of the Rce1 protease disrupt Ras membrane localization in human cells. |
causal interaction
therapeutic application
unassigned |
3
4
0 |
| 2.5.1.21 | Glioblastoma |
23566417 |
?v?3 Integrin and Fibroblast growth factor receptor 1 (FGFR1): Prognostic factors in a phase I-II clinical trial associating continuous administration of Tipifarnib with radiotherapy for patients with newly diagnosed glioblastoma. |
causal interaction
ongoing research
therapeutic application
unassigned |
1
4
3
0 |
| 2.5.1.21 | Leukemia, Myeloid, Acute |
18160667 |
A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia. |
therapeutic application
unassigned |
4
0 |
| 2.5.1.21 | Tauopathies |
30918111 |
A farnesyltransferase inhibitor activates lysosomes and reduces tau pathology in mice with tauopathy. |
ongoing research
therapeutic application
unassigned |
3
4
0 |
